SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company that went public through a merger with Big Rock Partners Acquisition Corp, a blank-check vehicle sponsored by Big Rock Partners that completed its IPO in 2019. The company focuses on developing human polyclonal antibodies produced in genetically engineered cattle, with a pipeline directed at infectious diseases and immune-mediated conditions. This 10-Q, filed in May 2021, was submitted in the period preceding the close of the business combination, which was finalized in October 2021 and brought SABS to the Nasdaq exchange. Investors seeking complete filing histories, sponsor profiles, and deal analytics for SABS and hundreds of other SPACs can sign up for full data access at SpacDesk.